The role of IL-2 secreted from genetically modified tumor cells in the establishment of antitumor immunity

Rajat Bannerji, Crispinita D. Arroyo, Carlos Cordon-Cardo, Eli Gilboa

Research output: Contribution to journalArticle

88 Citations (Scopus)

Abstract

Although the importance of CD4+ T cells for the induction of an effective CD8+ cytolytic T cell response is well documented, the mechanism by which MHC class II-negative tumor cells recruit CD4+ T help is not well understood. We have previously shown that IL-2 or IFN-γ gene-modified CMS-5 tumor cells do not grow in syngeneic mice; however, mice which rejected the cytokine-secreting tumor cells develop a protective immune response against a challenge with parental tumor cells. Here we show that rejection of IL-2- secreting CMS-5 cells is not mediated by T cells. However, establishment of a protective immune response against CMS-5 tumor cells requires the presence of both CD4+ and CD8+ T cell subsets during the period of immunization with IL-2-secreting CMS-5 cells as well as during the effector phase. Extensive histologic analysis has failed to detect the presence of T cells at the site of immunization with either IL-2- or IFN-γ-secreting CMS-5 cells. The main infiltrate at the site of inoculation with IL-2-secreting CMS-5 cells consisted of NK cells that appeared to play a role in their rejection. The predominant infiltrate at the site of inoculation with IFN-γ-secreting CMS- 5 cells consisted of macrophages. These observations argue against a direct role for the intact tumor cell in presenting either T helper or CTL epitopes to the immune system, and support the view that specialized APC are responsible for the in vivo priming of a T cell response against MHC class I- restricted Ag.

Original languageEnglish
Pages (from-to)2324-2332
Number of pages9
JournalJournal of Immunology
Volume152
Issue number5
StatePublished - Mar 1 1994
Externally publishedYes

Fingerprint

Interleukin-2
Immunity
Neoplasms
T-Lymphocytes
Immunization
T-Lymphocyte Subsets
Natural Killer Cells
Epitopes
Immune System
Macrophages
Cytokines

ASJC Scopus subject areas

  • Immunology

Cite this

The role of IL-2 secreted from genetically modified tumor cells in the establishment of antitumor immunity. / Bannerji, Rajat; Arroyo, Crispinita D.; Cordon-Cardo, Carlos; Gilboa, Eli.

In: Journal of Immunology, Vol. 152, No. 5, 01.03.1994, p. 2324-2332.

Research output: Contribution to journalArticle

Bannerji, Rajat ; Arroyo, Crispinita D. ; Cordon-Cardo, Carlos ; Gilboa, Eli. / The role of IL-2 secreted from genetically modified tumor cells in the establishment of antitumor immunity. In: Journal of Immunology. 1994 ; Vol. 152, No. 5. pp. 2324-2332.
@article{242ad4fcf2894dbfa4156c59d55445b2,
title = "The role of IL-2 secreted from genetically modified tumor cells in the establishment of antitumor immunity",
abstract = "Although the importance of CD4+ T cells for the induction of an effective CD8+ cytolytic T cell response is well documented, the mechanism by which MHC class II-negative tumor cells recruit CD4+ T help is not well understood. We have previously shown that IL-2 or IFN-γ gene-modified CMS-5 tumor cells do not grow in syngeneic mice; however, mice which rejected the cytokine-secreting tumor cells develop a protective immune response against a challenge with parental tumor cells. Here we show that rejection of IL-2- secreting CMS-5 cells is not mediated by T cells. However, establishment of a protective immune response against CMS-5 tumor cells requires the presence of both CD4+ and CD8+ T cell subsets during the period of immunization with IL-2-secreting CMS-5 cells as well as during the effector phase. Extensive histologic analysis has failed to detect the presence of T cells at the site of immunization with either IL-2- or IFN-γ-secreting CMS-5 cells. The main infiltrate at the site of inoculation with IL-2-secreting CMS-5 cells consisted of NK cells that appeared to play a role in their rejection. The predominant infiltrate at the site of inoculation with IFN-γ-secreting CMS- 5 cells consisted of macrophages. These observations argue against a direct role for the intact tumor cell in presenting either T helper or CTL epitopes to the immune system, and support the view that specialized APC are responsible for the in vivo priming of a T cell response against MHC class I- restricted Ag.",
author = "Rajat Bannerji and Arroyo, {Crispinita D.} and Carlos Cordon-Cardo and Eli Gilboa",
year = "1994",
month = "3",
day = "1",
language = "English",
volume = "152",
pages = "2324--2332",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "5",

}

TY - JOUR

T1 - The role of IL-2 secreted from genetically modified tumor cells in the establishment of antitumor immunity

AU - Bannerji, Rajat

AU - Arroyo, Crispinita D.

AU - Cordon-Cardo, Carlos

AU - Gilboa, Eli

PY - 1994/3/1

Y1 - 1994/3/1

N2 - Although the importance of CD4+ T cells for the induction of an effective CD8+ cytolytic T cell response is well documented, the mechanism by which MHC class II-negative tumor cells recruit CD4+ T help is not well understood. We have previously shown that IL-2 or IFN-γ gene-modified CMS-5 tumor cells do not grow in syngeneic mice; however, mice which rejected the cytokine-secreting tumor cells develop a protective immune response against a challenge with parental tumor cells. Here we show that rejection of IL-2- secreting CMS-5 cells is not mediated by T cells. However, establishment of a protective immune response against CMS-5 tumor cells requires the presence of both CD4+ and CD8+ T cell subsets during the period of immunization with IL-2-secreting CMS-5 cells as well as during the effector phase. Extensive histologic analysis has failed to detect the presence of T cells at the site of immunization with either IL-2- or IFN-γ-secreting CMS-5 cells. The main infiltrate at the site of inoculation with IL-2-secreting CMS-5 cells consisted of NK cells that appeared to play a role in their rejection. The predominant infiltrate at the site of inoculation with IFN-γ-secreting CMS- 5 cells consisted of macrophages. These observations argue against a direct role for the intact tumor cell in presenting either T helper or CTL epitopes to the immune system, and support the view that specialized APC are responsible for the in vivo priming of a T cell response against MHC class I- restricted Ag.

AB - Although the importance of CD4+ T cells for the induction of an effective CD8+ cytolytic T cell response is well documented, the mechanism by which MHC class II-negative tumor cells recruit CD4+ T help is not well understood. We have previously shown that IL-2 or IFN-γ gene-modified CMS-5 tumor cells do not grow in syngeneic mice; however, mice which rejected the cytokine-secreting tumor cells develop a protective immune response against a challenge with parental tumor cells. Here we show that rejection of IL-2- secreting CMS-5 cells is not mediated by T cells. However, establishment of a protective immune response against CMS-5 tumor cells requires the presence of both CD4+ and CD8+ T cell subsets during the period of immunization with IL-2-secreting CMS-5 cells as well as during the effector phase. Extensive histologic analysis has failed to detect the presence of T cells at the site of immunization with either IL-2- or IFN-γ-secreting CMS-5 cells. The main infiltrate at the site of inoculation with IL-2-secreting CMS-5 cells consisted of NK cells that appeared to play a role in their rejection. The predominant infiltrate at the site of inoculation with IFN-γ-secreting CMS- 5 cells consisted of macrophages. These observations argue against a direct role for the intact tumor cell in presenting either T helper or CTL epitopes to the immune system, and support the view that specialized APC are responsible for the in vivo priming of a T cell response against MHC class I- restricted Ag.

UR - http://www.scopus.com/inward/record.url?scp=0028270141&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028270141&partnerID=8YFLogxK

M3 - Article

C2 - 7907636

AN - SCOPUS:0028270141

VL - 152

SP - 2324

EP - 2332

JO - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 5

ER -